GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Total Liabilities
Latest total liabilities as of September 2025: ₹19.57 Billion INR
Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has total liabilities worth ₹19.57 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GlaxoSmithKline Pharmaceuticals Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GlaxoSmithKline Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vantage Towers AG
PINK:VTWRF
|
USA | $5.49 Billion |
|
Veris Gold Corp
PINK:YNGFF
|
USA | $201.89 Million |
|
Fila Holdings Corp
KO:081660
|
Korea | ₩2.75 Trillion |
|
Dottikon Es Holding AG
SW:DESN
|
Switzerland | CHF348.89 Million |
|
Jiangsu Wujiang Rural Coml Bk
SHG:603323
|
China | CN¥208.05 Billion |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
China | CN¥15.84 Billion |
|
Verint Systems Inc
NASDAQ:VRNT
|
USA | $896.45 Million |
|
DEUTZ Aktiengesellschaft
PINK:DEUZF
|
USA | $984.64 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down GlaxoSmithKline Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
The table below shows the annual total liabilities of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹21.57 Billion | +21.24% |
| 2024-03-31 | ₹17.79 Billion | +12.22% |
| 2023-03-31 | ₹15.85 Billion | -19.54% |
| 2022-03-31 | ₹19.70 Billion | +22.06% |
| 2021-03-31 | ₹16.14 Billion | +22.76% |
| 2020-03-31 | ₹13.15 Billion | -25.77% |
| 2019-03-31 | ₹17.71 Billion | -6.28% |
| 2018-03-31 | ₹18.90 Billion | +89.59% |
| 2017-03-31 | ₹9.97 Billion | -26.15% |
| 2016-03-31 | ₹13.50 Billion | +72.99% |
| 2015-03-31 | ₹7.80 Billion | -31.54% |
| 2014-03-31 | ₹11.40 Billion | +5.38% |
| 2013-03-31 | ₹10.82 Billion | -4.29% |
| 2012-03-31 | ₹11.30 Billion | +31.57% |
| 2011-03-31 | ₹8.59 Billion | +20.68% |
| 2010-03-31 | ₹7.12 Billion | -4.47% |
| 2009-03-31 | ₹7.45 Billion | +13.69% |
| 2008-03-31 | ₹6.55 Billion | +12.14% |
| 2007-03-31 | ₹5.84 Billion | +3.83% |
| 2006-03-31 | ₹5.63 Billion | +14.80% |
| 2005-03-31 | ₹4.90 Billion | -- |